ReviewThe mental health clinician2018
Review of pharmacotherapy for smoking cessation in patients with schizophrenia.
Review in The mental health clinician, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacotherapy for smoking cessation in schizophrenia: a systematic review.Expert opinion on pharmacotherapy · 2020Pooled it
- Effects of varenicline on the serum levels of olanzapine in male patients with Schizophrenia: a randomized controlled trial.Frontiers in psychiatry · 2023Article
- Palliative and high-intensity end-of-life care in schizophrenia patients with lung cancer: results from a French national population-based study.European archives of psychiatry and clinical neuroscience · 2021Article
- The clinical characterization of the patient with primary psychosis aimed at personalization of management.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2021Article
- Association between lower estimated premorbid intelligence quotient and smoking behavior in patients with schizophrenia.Schizophrenia research. Cognition · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Smoking cessation is a chronic issue surrounding individuals with schizophrenia. It is estimated that up to 90% of patients diagnosed with schizophrenia smoke cigarettes. The purpose of this article is to provide a nonsystematic review of the efficacy of smoking cessation interventions as well as to explore the potential neuropsychiatric adverse effects of these agents in patients with schizophrenia. Eighteen studies were found and included in the review. Overall, nicotine replacement therapy, bupropion, and varenicline have all proven their effectiveness at either promoting smoking abstinence or a significant reduction in cigarette use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.